Commonwealth Consolidated Regulations

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS 1960 - REG 37JA

         (1)   Subregulation (2) applies if:

                (a)    a listed brand of a pharmaceutical item is in a supplementary disclosure cycle A; and

               (b)    the data collection period in the supplementary disclosure cycle ends at the end of 31 January in a year.

         (2)   Another reporting period in that data collection period begins on 1 October in the year before the year and ends at the end of 31 January in the year.

         (3)   Subregulation (4) applies if:

                (a)    a listed brand of a pharmaceutical item is in a supplementary disclosure cycle B; and

               (b)    the data collection period in the supplementary disclosure cycle ends at the end of 31 May in a year.

         (4)   Another reporting period in that data collection period begins on 1 April in the year and ends at the end of 31 May in the year.

         (5)   Subregulation (6) applies if:

                (a)    a listed brand of a pharmaceutical item is in the interim supplementary disclosure cycle; and

               (b)    the data collection period in the disclosure cycle ends at the end of 31 May 2012.

         (6)   Another reporting period in that data collection period begins on 1 April 2012 and ends at the end of 31 May 2012.

Note    For transitional arrangements, see Part 2 of the National Health (Pharmaceutical Benefits) Amendment Regulations 2010 (No. 5).